50
Participants
Start Date
November 7, 2022
Primary Completion Date
November 20, 2024
Study Completion Date
December 31, 2026
Neoadjuvant Olaparib monotherapy group
Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
Neoadjuvant combination therapy with olaparib plus durvalumab
Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
Research Site, Brussels
Research Site, Melbourne
Research Site, Liège
Research Site, Salzburg
Research Site, Rankweil
Research Site, Barcelona
Research Site, Cáceres
Research Site, A Coruña
Research Site, Philadelphia
Research Site, Hamburg
Research Site, Lleida
Research Site, Madrid
Research Site, Málaga
Research Site, Hanover
Research Site, Bologna
Research Site, Seville
Research Site, Seville
Research Site, Modena
Research Site, Kfar Saba
Research Site, Essen
Research Site, Valencia
Research Site, Meldola
Research Site, Cologne
Research Site, Heidelberg
Research Site, Rehovot
Research Site, Loveland
Research Site, Greeley
Research Site, München
Research Site, Augsburg, by
Research Site, Jerusalem
Research Site, Portland
Research Site, Ramat Gan
Research Site, Boston
Research Site, Roma
Research Site, Barcelona
Research Site, Hospitalet deLlobregat
Research Site, Nottingham
Lead Sponsor
AstraZeneca
INDUSTRY